Freedom Biosciences is a biotechnology startup that specializes in the development of next-generation neuropsychiatric therapeutics. The company is led by a team of experts in the fields of science and business, including Dr. John Krystal, a pioneering researcher in psychiatry, and Dina Burkitbayeva, co-founder of PsyMed Ventures.

The company's primary focus is on creating a new class of antidepressants, with a particular emphasis on ketamine-based and neuropsychiatric pharmaceuticals. These are designed to provide more effective treatment options for people suffering from severe mental health disorders. The company's work is driven by the recognition of the need for novel treatment options, as witnessed by Dr. Krystal in his work with military veterans and those living with severe mental health and substance use disorders.

Freedom Biosciences operates in the biotechnology and pharmaceutical industry, serving clients who are in need of effective treatments for mental health disorders. The company's business model revolves around the research, development, and commercialization of innovative neuropsychiatric therapeutics.

The company generates revenue through the development and sale of these therapeutics. It is currently working on a pipeline of innovative clinical and preclinical stage programs, including therapies for treatment-resistant depression and comorbid major depressive disorder & substance use disorder.

In summary, Freedom Biosciences is a biotech startup that is developing innovative neuropsychiatric therapeutics to provide more effective treatment options for people suffering from severe mental health disorders.

Keywords: Biotechnology, Neuropsychiatric Therapeutics, Antidepressants, Ketamine-Based Pharmaceuticals, Mental Health Disorders, Treatment Options, Research and Development, Clinical and Preclinical Stage Programs, Treatment-Resistant Depression, Comorbid Major Depressive Disorder & Substance Use Disorder.